QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Article 30 Referral in EU Medicines Regulation

Test your understanding of the concepts covered by Article 30 Referral in EU Medicines Regulation: Divergent National Decisions and Harmonisation.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which implementation package would best support inspection readiness after an Article 30 referral?

Only the final press release and the current package leaflet A controlled record linking the divergence, referral documents, questions, responses, opinions, decision, translations and national implementation evidence Only meeting minutes from the CHMP plenary A list of affected countries without dates or supporting documents

Question 2 of 10 What is the consequence if a re-examination request is withdrawn?

The initial CHMP opinion immediately becomes the final opinion The Commission automatically reopens the scientific assessment The referral is permanently cancelled and all national authorisations lapse A new Article 30 referral is automatically initiated

Question 3 of 10 Why is translation of the final harmonised product information a regulatory-control activity rather than merely an editorial task?

Translations determine the original scientific conclusions Translation can affect the accuracy and consistency of the legally implemented product information across Member States Translations are optional if the English text is publicly available Linguistic review permits Member States to adopt different scientific positions

Question 4 of 10 Which party may, subject to the statutory conditions, initiate an Article 30 referral?

Only the concerned national competent authority Only the European Commission A Member State, the European Commission, the applicant or the marketing authorisation holder Only the QPPV acting on behalf of the MAH

Question 5 of 10 Which statement correctly describes the relationship between rapporteur assessment reports and the CHMP opinion?

The rapporteur report is automatically the final committee decision The rapporteur report provides a scientific evaluation for consideration by the full CHMP, which adopts the formal opinion The rapporteur report is prepared only after the Commission decision The report replaces the need for MAH responses

Question 6 of 10 Which control is most important for ensuring that an MAH receives time-critical EMA procedural communications?

Relying on an individual employee to monitor public meeting highlights Registering and maintaining the designated procedural contact in IRIS, with access and backup arrangements Waiting for national authorities to forward every EMA message Using only the company pharmacovigilance mailbox without checking the applicable platform

Question 7 of 10 What does a List of Outstanding Issues generally indicate?

That the referral was never formally initiated That material issues remain unresolved after the initial assessment and responses That the Commission has already adopted its binding decision That the MAH has withdrawn its marketing authorisation

Question 8 of 10 According to the article's described EMA guidance, what is the critical first deadline for an MAH seeking re-examination?

Notify EMA in writing of the intention within 15 calendar days of receipt of the CHMP opinion Submit detailed grounds within 15 working days of the Commission decision Notify EMA within 60 calendar days after national implementation Submit a new application within 30 calendar days of the CHMP meeting

Question 9 of 10 Why is a simple comparison of national SmPC wording insufficient to establish that an Article 30 referral is appropriate?

National product information is never relevant to Article 30 The legal assessment depends on the underlying national regulatory decisions, not wording differences alone Only differences in package leaflets can trigger Article 30 Article 30 applies only when all Member States have identical authorisation histories

Question 10 of 10 Which submission approach is most appropriate when an MAH proposes harmonised product information?

Submit only the preferred final wording, without describing national differences Describe the national positions, identify the divergence, link the proposed wording to evidence and justify material changes Use the wording from the largest Member State automatically Treat the exercise as an editorial comparison without scientific analysis

Professional Knowledge Assessment: Article 30 Referral in EU Medicines Regulation

Cookie Settings